The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The proposed transaction will be effected as a share swap
Consolidated revenue from operations stood at Rs. 111.05 crore
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
